Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) Director Faith Charles acquired 15,000 shares of the company’s stock in a transaction on Friday, November 13th. The shares were purchased at an average cost of $2.29 per share, with a total value of $34,350.00. Following the completion of the acquisition, the director directly owned 191,407 shares in the company, valued at approximately $438,322.03. The trade was a 8.50% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Abeona Therapeutics Trading Up 7.4%
Abeona Therapeutics stock opened at $2.60 on Tuesday. The company has a market cap of $148.59 million, a PE ratio of -2.43 and a beta of 1.50. Abeona Therapeutics Inc. has a 1 year low of $2.09 and a 1 year high of $7.65. The company’s 50-day moving average is $4.63 and its two-hundred day moving average is $5.38.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.09. The company had revenue of $13.49 million during the quarter, compared to analysts’ expectations of $14.82 million. Abeona Therapeutics had a negative net margin of 160.30% and a negative return on equity of 44.82%. Research analysts forecast that Abeona Therapeutics Inc. will post -0.97 EPS for the current year.
Analysts Set New Price Targets
A number of analysts have commented on ABEO shares. Wall Street Zen raised shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating on shares of Abeona Therapeutics in a research report on Friday, September 25th. Roth Capital assumed coverage on Abeona Therapeutics in a research note on Thursday, September 17th. They issued a “buy” rating and a $17.00 price target on the stock. Weiss Ratings lowered Abeona Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Tuesday, November 10th. Finally, UBS Group reaffirmed a “buy” rating on shares of Abeona Therapeutics in a research note on Friday, September 25th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.
Read Our Latest Stock Analysis on ABEO
Institutional Trading of Abeona Therapeutics
Hedge funds have recently modified their holdings of the company. Global Retirement Partners LLC grew its holdings in Abeona Therapeutics by 1,026.2% during the third quarter. Global Retirement Partners LLC now owns 4,978 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 4,536 shares during the period. Royal Bank of Canada increased its stake in Abeona Therapeutics by 49.6% in the first quarter. Royal Bank of Canada now owns 6,500 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 2,155 shares in the last quarter. Dimensional Fund Advisors LP acquired a new stake in Abeona Therapeutics in the first quarter worth $154,000. WINTON GROUP Ltd acquired a new stake in Abeona Therapeutics in the second quarter worth $256,000. Finally, Rangeley Capital LLC raised its holdings in Abeona Therapeutics by 4.2% in the first quarter. Rangeley Capital LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $269,000 after purchasing an additional 2,400 shares during the period. 80.56% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting Abeona Therapeutics
Investors following ABEO have been watching these headlines:
- Positive Sentiment: Director Faith Charles bought 15,000 shares for about $34,350, increasing her stake by 8.5% to 191,407 shares. The insider purchase may be viewed as a confidence signal. SEC filing
- Neutral Sentiment: HC Wainwright maintained its Buy rating. It raised its FY2026 EPS estimate to a loss of $0.96 from $1.15, while forecasting a $0.82 loss per share for FY2027. Abeona Therapeutics analyst coverage
- Negative Sentiment: The analyst lowered estimates across Q1–Q4 2027, including cutting FY2027 EPS to a loss of $0.82 from $0.49. These revisions suggest a weaker earnings outlook and could weigh on shares, partially offsetting the insider buying.
About Abeona Therapeutics
Abeona Therapeutics, Inc. is a biotechnology company focused on developing cell and gene therapies for serious and rare diseases. Its work includes treatments designed to address the underlying genetic causes of disease. The company’s lead product, ZEVASKYN (prademagene zamikeracel), is an autologous gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, a rare inherited skin disorder. Made from a patient’s skin cells, the therapy uses genetic modification to help cells produce type VII collagen and is applied to wounds.
Featured Articles
- Five stocks we like better than Abeona Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
